Evolving Treatment Landscape of HER2 -mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond.
Ioannis A VathiotisDimitrios BafaloukosKonstantinos N SyrigosGeorge SamonisPublished in: Cancers (2023)
Successful targeting of HER2 -activating mutations in DESTINY-Lung02 phase II study has led to the approval of the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) as second-line treatment in patients with non-small cell lung cancer (NSCLC). Despite the impressive results, several matters need to be addressed, including the clinical activity of T-DXd in patients with disease in the central nervous system as well as the role of T-DXd in the context of HER2 overexpression. Additionally, data regarding novel agents used to target HER2 continue to accumulate. This review highlights the challenges and unanswered questions that have emerged after the approval of T-DXd in patients with HER2 -mutant NSCLC.
Keyphrases
- phase ii study
- small cell lung cancer
- epidermal growth factor receptor
- cancer therapy
- signaling pathway
- cell proliferation
- magnetic resonance imaging
- randomized controlled trial
- transcription factor
- open label
- locally advanced
- squamous cell carcinoma
- big data
- radiation therapy
- single cell
- electronic health record
- drug delivery
- cerebrospinal fluid
- rectal cancer
- data analysis
- deep learning